The Tylenol Crisis: Exemplary Public Relations Case

UNSAFE PRODUCTS Even though corporations do not wish to cause harm to consumers, they have in fact all too often done so when the drive to maximize profit or survive in the marketplace has taken priority over concern for consumer safety. An massive range of consumer products including many foods, drugs and medical devices, vehicles, domestic products, and cosmetics have been acknowledged as dangerous to various degrees. Around 70,000 Americans are suspected to die yearly from product-related accidents, and millions more suffer incapacitating injuries at a cost of over $100 billion in property damage, lost wages insurance, litigation, and medical expenses. Even though certain products are intrinsically dangerous, much evidence suggests that corporations, in their almost single-minded pursuit of profit, have been negligent- sometimes criminally- in their disregard for consumer safety.

o Employees of the company would lack trust among themselves as well as will lose sense of community. o Community was misloaded by the company to treat the pain specified on the packaging relevant to that product. This would have resulted in going against the Corporate social responsibility that the company needs to follow.

Right now in the United States of America, there is a monopoly that exists that involves epinephrine auto-injectors. EpiPen is the United States only supplier of these auto-injectors because other brands have suffered setbacks and failures, patent protection laws, and because there are currently no generic versions of EpiPen in the United States (Johnson). This monopoly was not a problem until Mylan bought Meda AB in 2007 (Paton). “Since Mylan bought the rights to EpiPen in 2007, it has raised the price on 15 separate occasions, bringing the current list price to $608 for a two-pack up from about $50 a pen in 2007” (Mole). This has been a price increase of more than 500%, and this shows that Mylan has been using the monopoly to its advantage.

I. Importance: As American deaths from drug overdoses continue to rise in the United States, the nation is faced with a public health crisis so profound that in October 2017, President Trump declared the opioid epidemic to be a national public health emergency (Merica). President Trump’s declaration came after numerous studies indicating the danger opioid addiction posed; for example, a 2016 study entitled “Increases in Drug and Opioid-Involved Overdose Deaths—United States, 2010-2015” claimed that drug overdose deaths “nearly tripled during 1999-2014,” reaching a startling high 52,404 deaths in 2015 (Rudd, et al). These statistics are more than just disturbing revelations regarding the opioid crisis; they are evidence of a serious problem that is rapidly affecting the lives of more and more Americans every year. Death by overdose is not the only public policy concern, however, as millions of Americans are also addicted to prescription opioids.

Without patient’s being aware of how to power the drug was, it eventually leads to the Opioids Crisis in America which now put a horrible word for the doctors and companies when it all starts by one person abusing the opioid pill. President Donald J. Trump idea that he had in mind was stated in the article of America’s Opioid Crisis, “But he reinforced the idea that the victims are to blame with an offhand reference to LSD.” Which indeed has the fact that people are to blame for misusage of the

When OxyContin went off the market in 2012, a new drug came to raise, Fentanyl. Fentanyl is a potent, fast acting, synthetic pain killer; its potency is 100 times greater than morphine and about 50 times greater than heroin (FISCHER, 2016). It was marketed to cancer patients and those In severe chronic pain. Fentanyl was created by a company called Insys Therapeutics, INC. This drug is beginning to take Canada by storm, with its potency overdoses and deaths are happening across the country, it is almost impossible to turn of the news without the mention of this drug.

They didn’t want to lose out on any profits by going global. Since they were new to this line of business they partner with J&J’s McNeil division. J&J were an excellent choice to partner with to introduce Benecol to the global market. The only hurdles stopping Benecol to be introduced into the world were regulatory issues. It would be difficult to bring Benecol to the market as quickly as possible in Europe and even more so in US.

Problem Identification: Cialis was trying to enter into the market which was already well established by its competitors. The revenues of Pfizer were sky touching and they already had a mechanism to sell Viagra at very bottom level. They invested lot of money for branding Viagra using celebrities in TV commercials. Pfizer also had huge sales teams going to doctors and convince them to prescribe Pfizer’s medication to the patients.

Prescription drugs (opiates only) have caused over 165,000 deaths within the last 15 years and is currently on the rise. Over 2 million Americans in 2014 were addicted to Opiate prescription narcotics. The most troubling fact is listed directly on the Center for Disease Control and Prevention (CDC) website: “As many as 1 in 4

Research and development is a very important part of their value chain. It is linked throughout almost every aspect of their priority topics including product quality, reliability, and safety, access and affordability, and all the way to their product end of life. Research and development at Johnson & Johnson is used to create new products and figure out ways to improve their old products. Since there are many illnesses that do not have a cure, Johnson & Johnson invests in

Often the work conducted in Kodak’s research labs related to digital technology was left unappreciated by other by the rest of the company who still believed in silver halide film as the industry standard. Kodak also faltered in its ability to put its acquisitions to use. In addition to some questionable acquisitions, Kodak’s shear inability to convert the acquired technical expertise to successful knew products proved many of its acquisitions to be a waste of time and resources. As an example, Sterling Drug was acquired in 1988 by Kodak for $5.1 billion. The company was purchased solely because the Kodak managerial team felt that the pharmaceutical industry was at its core a chemical business like itself.

Johnson & Johnson also have many first-aid and household products among their range. For example a Band-Aid line, medications, baby products, skin and beauty products, facial wash and contact lenses. They have three extended divisions to their organization which is Consumer healthcare, medical devices and pharmaceuticals. It was named after Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson. It produced its first products in the year 1886 and incorporated in 1887.

In terms of Johnson and Johnson handling the situation, they first pulled all Tylenol for the shelves in the Chicago area before recalling the product nationwide, costing the company over 100 million dollars. Second, Johnson and Johnson found that it was necessary to let doctors, hospitals, and distributors know by explaining the situation and the recall via mailgram messages. Third, the company had created a toll-free phone line

Kraft Heinz Case Study Executive Summary Problem Statement The focal problem that Kraft Heinz Company (KHC) faces is the decrease in demand of packaged-foods, while trying to increase revenue. Analysis This analysis studies Kraft Heinz Company’s strategy, competitive position in the market, problems being faced, and the company’s financials.

There is large investments being made in new technology to reduce production times and improve quality so that patients receive the best quality products in the swiftest manner. Patient care is at the heart of Janssen as clinical trials are on site to always try to gain more information on the potential products to improve. Janssen is a subsidiary of Johnson & Johnson, so to look at the organisation structure it must fall under J&J’s structure first. J&J’s organisation can be split into three main factions; Consumer healthcare, medical devices and pharmaceuticals.